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Abstract
Background: Low cardiac output (LCO) after corrective surgery remains a serious complication in pediatric
congenital heart diseases (CHD). In the case of refractory LCO, extra corporeal life support (ECLS) extra corporeal
membrane oxygenation (ECMO) or ventricle assist devices (VAD) is the final therapeutic option. In the present
study we have reviewed the outcomes of pediatric patients after corrective surgery necessitating ECLS and
compared outcomes with pediatric patients necessitating ECLS because of dilatated cardiomyopathy (DCM).
Methods: A retrospective single-centre cohort study was evaluated in pediatric patients, between 1991 and 2008,
that required ECLS. A total of 48 patients received ECLS, of which 23 were male and 25 female. The indications for
ECLS included CHD in 32 patients and DCM in 16 patients.
Results: The mean age was 1.2 ± 3.9 years for CHD patients and 10.4 ± 5.8 years for DCM patients. Twenty-six
patients received ECMO and 22 patients received VAD. A total of 15 patients out of 48 survived, 8 were discharged
after myocardial recovery and 7 were discharged after successful heart transplantation. The overall mortality in
patients with extracorporeal life support was 68%.
Conclusion: Although the use of ECLS shows a significantly high mortality rate it remains the ultimate chance for
children. For better results, ECLS should be initiated in the operating room or shortly thereafter. Bridge to heart
transplantation should be considered if there is no improvement in cardiac function to avoid irreversible
multiorgan failure (MFO).
Introduction
Despite technical improvements in congenital heart sur-
gery, mortality as a result of cardiac dysfunction after
corrective surgery remains a serious problem. A total of
1 to 5% of these patients will require some form of
mechanical support [1-3]. In addition, children with
dilatated cardiomyopathy (DCM) may also require extra-
corporeal life support (ECLS) due to multiorgan dys-
function if conservative medical treatment is inadequate.
In this retrospective single center analyzes we present
our experience with both extra corporeal membrane
oxygenation (ECMO) and ventricle assist device (VAD)
for pediatric patients requiring ECLS at our institution.
We reviewed the outcomes of pediatric patients necessi-
tating ECLS after corrective surgery and compared
outcomes with pediatric patients necessitating ECLS
because of DCM. Our aim is to report the prognosis of
children undergoing ECLS and to compare the out-
comes of the two main diseases associated with high
mortality even in canters with ECLS possibilities.
Materials and methods
A total of 48 patients received ECLS, of which 23 were
male and 25 female. The indications for ECLS included
CHD in 32 cases and DCM in 16 patients. The mean
age was 1.2 ± 3.9 years for CHD patients and 10.4 ± 5.8
years for DCM patients. Twenty-six patients received
ECMO; 22 patients in CHD group vs. 4 patients in
DCM group and 22 patients received VAD; 10 patients
in CHD group vs. 12 patients in DCM group.
The preoperative diagnoses in CHD group included:
14 transposition of the great vessels, 1 Bland-White-
Garland syndrome, 6 tetralogy of Fallot, 2 hypoplasia of
the aortic arch, 2 total anomalous pulmonary vein
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any medium, provided the original work is properly cited.connection, 4 univentricular heart and 3 ventricular sep-
tal defect. Patient characteristics are given in Table 1.
Causes of DCM are not reported in this study since
myocardial biopsies was not available in all patients.
Indication for an ECLS is achieved after failing attempts
weaning off from cardiopulmonary bypass (CPB) under
pharmacological support or clinical deterioration and
necessitating resuscitation.
The aim of ECLS initiation was:
￿ The maintance of systemic circulation
￿ Recovery of multiple organ failure
￿ Bridge to transplantation
The patients received an ECLS support in case of:
￿ Inability to wean from CPB in the operation room
￿ Clinical deterioration: Despite optimal pharmacologi-
cal support
￿ Low output syndrome,
￿ Mean arterial pressure <60 mmHg,
￿ Ejection fraction <25%
￿ Cardiac index <2 l/min/kg
￿ Diuresis <1 ml/min/kg
￿ Central venous pressure >15 mmHg
￿ Left atrial pressure > 18 mmHg
Cannulation of ECLS was performed either in the
operating room or in the intensive care unit. The
patient was given 30-100 units/kg of heparin, with
ECMO; the activated clotting time is usually maintained
between 170 and 200 seconds compared to 140-160 sec-
onds in children on VAD. On institution of ECMO, ino-
tropic support was weaned to minimal levels to keep
mean arterial blood pressures at 50 mm Hg. Flow rates
were maintained depending on hemodynamic situation
until the SVO2 was 75%. The mean blood pressure
range for neonates on ECMO is 40-65 mm Hg. Nor-
mothermia was maintained in all patients. In VAD
group anticoagulation was started 24 hours after
implantation after chest tubes removal Warfarin sodium
(Coumadin; Bristol-Myer Squibb Company, Princeton,
NJ) was initiated to maintain an INR value of 2.5-3.5.
The used devices were MEDOS HIA-VAD (MEDOS
Medizintechnik GmbH, Stollberg, Germany) - a pneu-
matically actuated blood pump, Thoratec paracorporeal
pneumatic VAD (Thoratec Corp, Plesanton, CA), Car-
dioWest total artificial heart (TAH) (SynCardia Systems,
Tucson, AZ, USA). Novacor LVAD (Baxter, Oakland,
NJ), ECMO with an oxygenator (Carmeda Maxima;
Medtronic, Düsseldorf, Germany), and centrifugal pump
(Biomedicus; Medtronic). None of the patients had an
intra-aortic balloncounter pulsation (IABP).
Echocardiography is used to evaluate the ventricular
function after 24 hours. Our criteria to initiate a left
VAD-system included: good right ventricular contrac-
tion, adequate oxygenation and right atrial (RA) pres-
sure <12 mmHg. Reducing the flow rate should allow to
maintain adequate left ventricle (LV) ejection with left
atrial (LA) pressure of 8-10 mmHg. If right ventricular
(RV) function was poor and if patients did not show
improvement, they should be converted to an ECMO
for better oxygenation or they received an extra support
like biventricular assist device (BVAD) or right ventricu-
lar assist device (RVAD. In cases of right ventricular
failure, therapeutic measures included volume followed
by nitric oxide inhalation, inotropic agents, phospho-
diesterase type III inhibitors and prostaglandin depend-
ing on hemodynamic situation for each patient
individually [4].
The Indications for BVAD are
￿ MOF
￿ cardiac failure
￿ CVP >20 mmHg
￿ PAP/CVP gradient < 4 mmHg
￿ PVR >500 dyn/sec/cm-5
Statistical evaluation
Statistical analysis was performed using commercially
available statistics software (Statistica 5.1., StatSoft Inc.,
Tulsa, OK, USA). Statistics were performed using
Mann-Whitney U test for nonparametric continuous
data and x2-test. Patient survival rates were calculated
according to the Kaplan-Meier life table method (Fig-
ure 1). Statistical difference was considered at p < 0.05.
Results
There was a significant difference in age and weight
between the groups. DCM patients were older (10.4 ±
Table 1 Clinical characteristics
Characteristics DCM
patients
(n = 16)
Congenital
patients
(n = 32)
p-
value
Age at surgery (years) 10.4 ± 5.8 1.2 ± 3.9 0.007
Weight 43 ± 29.2 6.9 ± 13.1 0.0001
Male/female 6/10 17/15 0.30
CPR before ECLS 1 (6.25%) 9 (28.1%) 0.078
CVVH 1 (6.25%) 11 (34.4%) 0.03
HTX 6 (37.5%) 1 (3.13%) 0.001
Bleeding with ECLS 2 (12.5%) 12 (37.5%) 0.07
Pump head exchange 0 5 (15.6%) 0.09
Duration of ECLS (days) 48.5 ± 78.5 7.8 ± 12.1 0.001
Survival after ECLS (days) 563.4 ±
929.4
464.2 ± 848.6 0.58
ECMO
Assist device(LVAD/RVAD/
BVAD)
4 (25%)
12 (75%)
22 (69%)
10 (31%)
0.004
Mortality 12 (75%) 21 (65.6%) 0.50
CPR: cardiopulmonary resuscitation, CVVH: continuous venous-venous
hemofiltration, HTX: heart transplantation, ECLS: extracorporeal life support,
ECMO: extracorporeal membrane oxygenation, LVAD: left ventricle assist
device, RVAD: right ventricle assist device, BVAD: biventricular assist device.
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(43 ± 29.2 vs. 6.9 ± 13.1; p = 0.0001) than congenital
patients. Gender achieved no statistically difference
between the groups. Acute renal failure, which had to
treated with continuous veno venous hemofiltration
(CVVH), were more frequent in congenital patients than
in DCM patients (11 vs. 1; p = 0.03). In DCM patients
were more heart transplantations performed than in
congenital patients (6 vs. 1; p = 0.001). Furthermore, the
duration of ECLS was significant longer in DCM
patients than in congenital patients (48.5 ± 78.5 vs. 7.8
± 12.1; p = 0.001). In DCM patients more assist device
(LVAD/RVAD/BVAD) were used and less ECMO than
in congenital patients (p = 0.004). There were no statis-
tically significances observed in bleeding with ECLS,
pump head exchange, and survival after ECLS.
T h em o r t a l i t yw a sq u i t eu n i f o r ma c r o s st h eg r o u p s
and was analyzed with Logrank test (p = 0.65), as shown
in Figure 1.
Discussion
The general indication for ECLS is inadequate organ
perfusion due to ventricular dysfunction. The criteria
and guidelines for choosing correct type of ECLS
remains variable and controversial since heterogeneous
group of patients are effected whose outcome is greatly
influenced by multiple demographic, anatomic, clinical,
surgical and post operative variables. The selection of
device for the individual patients must be taken in
consideration. The decision to implant an ECLS is based
not only on the hemodynamic situation, but also the
status of organ function. We must take into considera-
tion that many post surgical problems are likely attribu-
table to the preoperative condition of the patient, thus it
is imperative to decide on possible implantation of a
device before multi organ failure occurs. ECLS plays an
important role as an alternative to support patients who
might not otherwise survive - patients with intractable
heart failure, low output or consequent MOF.
Complex CHD corrective operations mostly need
postoperative support some because of late presentation
and subsequent left ventricular failure, some because of
residual lesions, coronary ischemia, poor myocardial
protection and technical problems. All those factors
increase mortality and need of ECLS. ECMO is more
widely used in the pediatric population for short-term
support and biventricular dysfunction Some authors
confirm that ECMO is superior to VAD in CHD correc-
tive surgery with cyanotic lesions with cardiac shunts,
pulmonary hypertension and respiratory failure, whereas
VAD systems are often indicated for univenticular fail-
ure - for mid to long-term assistance [5,6].
IABP is not adequate for these critical situations; the
optimal approach to preserve end organ function is
instituting VAD or ECMO support before extended per-
iods of LCO, arrhythmia or cardiac arrest.
Renal failure is a predictor of high mortality in VAD
patients. Rapidly deteriorating patients should lead
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Figure 1 Cumulative survival analysis of both groups as Kaplan-Meier survival function. (Logrank test: p = 0.65).
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tion of ECLS [2,7,8].
The overall hospital survival for pediatric patients
managed with ECLS ranges between 38% and 53%, with
long-term survival of infants and children at our institu-
tion of 31% (similar to that reported rates above) [9-17].
Nevertheless, the use of ECLS has a significantly high
mortality rate associated with cardiopulmonary failure,
multi-organ dysfunction, neurological dysfunction, defi-
ciency of coagulation factors and mechanical factors
[18]. It should be strongly considered that the mortality
in those children ranged up to 90% if they do not
receive any supports [2].
The mechanical complications have an incidence of
27%, including: oxygenator failure, clots in the circuit,
pump malfunction, and presence of air in the circuit.
These complications correspond to long run times [19].
Moreover, ECMO and centrifugal pumps require high
levels of anticoagulation, which increases the risk of
bleeding. With ECMO, the activated clotting time is
usually maintained between 170 and 200 seconds com-
p a r e dt o1 4 0 - 1 6 0s e c o n d si nc h i l d r e no nV A D .T h e r e -
fore, bleeding is the major complication of ECMO, and
the most common sites for bleeding are cannulation and
surgical sites [20].
However, we found that re-exploration for bleeding
did not influence the overall clinical outcome [13].
The importance of brain protection and early identifi-
cation of cerebral injury indicates the importance of
early ECLS initiation. Neurological events in ECLS vary
from 11 to 45% (19). Decision on bridging to heart
transplantation, weaning off or device withdrawal
depends on evaluation of neurological events The ELSO
registry data indicated that cardiopulmonary resuscita-
tion (CPR) before the initiation of ECMO does not have
a negative impact on outcome, contrarily CPR in the
pre-ECLS period improves survival rates of up to 60%
among neonates [19].
The estimated weaning rate from ECMO is 43% [21]
and poor prognosis has been reported in patients treated
by ECMO for longer than 8 or 10 days [17,20,22].
Unfortunately high mortality rates are expected in
DCM patients because of lack of heart transplantation
opportunities, delay in referral for heart transplantation
and subsequent development of MOF. In case of heart
transplantation possibilities the literature shows an
encouraging survival rate over 44% in patients bridged
to cardiac transplantation and a 12 month survival of
62% to 88% [17,19,23-26]. In our experience, the appli-
cation of mechanical circulatory support has also been
useful as a bridge to heart transplantation with a survi-
val rate of 71%, which correlates with our previous
paper reviewing the outcome of pediatric heart recipi-
ents with CHD and DCM [26].
It is important to note that this study had some limita-
tions. Although we reviewed a relatively large number of
patients between 1991 an 2008, this remains a retrospec-
tive study. A heterogeneous group of patients are affected
whose outcome is greatly influenced by multiple demo-
graphic, anatomic, clinical, s u r g i c a la n dp o s to p e r a t i v e
variables. There were data elements, i.e. lactate level, car-
diac biopsy results and echocardiography not available
for the entire cohort. Furthermore, a complete neurologi-
cal evaluation was not always available, thus embolic or
ischemic cerebrovascular events were not analyzed.
Conclusion
ECMO and VAD remains the mainstay of mechanical
circulatory support for children. The progress and devel-
opment of ECLS is on-going and may possibly, in the
near future, become a more effective and rapid support
treatment option. ECMO, rather than VAD, may
become the first line of treatment of choice - with faster
initiation and fewer complications. For better results,
ECLS should be initiated in the operating room or
shortly thereafter to avoid prolonged hypoperfusion and
a catastrophic cardiac arrest. However, if there is no
improvement in cardiac function, than patients should
be bridged to VAD or heart transplantation.
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